Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Jul 11, 2016 → Aug 15, 2022
NCT ID
NCT02755597About Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax is a phase 3 stage product being developed by AbbVie for Relapsed/Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT02755597. Target conditions include Relapsed/Refractory Multiple Myeloma.
What happened to similar drugs?
0 of 9 similar drugs in Relapsed/Refractory Multiple Myeloma were approved
Approved (0) Terminated (1) Active (8)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02755597 | Phase 3 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma